Neoantigen Targeted Therapies Global Market Report 2025

Description

Neoantigen-targeted therapies represent a precision medicine approach focused on leveraging neoantigens within cancer cells. Neoantigens, distinct antigens arising from genetic abnormalities in cancer cells, become the target for harnessing the body's immune system to specifically identify and combat cancer.

These therapies fall into two main categories, monotherapy and combination therapy. Monotherapy involves utilizing a single medicine or therapeutic approach to address the disease. Immunotherapy options encompass DNA or RNA-based vaccines, protein-based vaccines, dendritic cell vaccines, and TIL-based therapies, with applications spanning colorectal cancer, renal cell carcinoma, non-small cell lung cancer, bone cancer, and gynecological cancer. Administration routes include intradermal, intravenous, and subcutaneous, while applications extend to medical research institutions, hospitals, clinics, and other healthcare settings.

The neoantigen targeted therapies market research report is one of a series of new reports from The Business Research Company that provides neoantigen targeted therapies market statistics, including the neoantigen targeted therapies industry global market size, regional shares, competitors with a neoantigen targeted therapies market share, detailed neoantigen targeted therapies market segments, market trends, and opportunities, and any further data you may need to thrive in the neoantigen targeted therapies industry. This neoantigen targeted therapies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The neoantigen targeted therapies market size has grown exponentially in recent years. It will grow from $3.4 billion in 2024 to $4.72 billion in 2025 at a compound annual growth rate (CAGR) of 38.7%. The growth in the historic period can be attributed to advancements in genomic sequencing, immunotherapy evolution, understanding tumor immunology, clinical success of checkpoint inhibitors, molecular profiling advancements

The neoantigen targeted therapies market size is expected to see exponential growth in the next few years. It will grow to $16.01 billion in 2029 at a compound annual growth rate (CAGR) of 35.7%. The growth in the forecast period can be attributed to advancements in bioinformatics, precision medicine expansion, neoantigen vaccine development, therapeutic combination strategies, biomarker validation. Major trends in the forecast period include neoantigen resistance management, neoantigen-primed adoptive cell therapies, neoantigen-based combinatorial therapies, integration of real-world data, enhanced predictive models.

The anticipated growth in the neoantigen targeted therapies market is primarily attributed to the increasing incidence of cancer cases. This refers to the rise in new cancer cases within a specific population during a given period. Neoantigen targeted therapies, often administered in combination, are instrumental in treating various types of cancer. In 2022, the American Cancer Society reported a substantial increase in new cancer cases in the United States, reaching 1.9 million. Additionally, 609,360 deaths were attributed to cancer in the same year, underscoring the profound impact of the disease. Consequently, the surge in cancer incidence is a key driver propelling the growth of the neoantigen targeted therapies market.

The increasing emphasis on precision oncology is expected to drive the growth of the neoantigen-targeted therapies market in the future. Precision oncology is a cancer treatment approach that utilizes detailed genetic and molecular information about a patient's tumor to guide the selection of targeted therapies. This approach employs neoantigen-targeted therapies by leveraging advanced genomic analysis to identify unique neoantigens expressed by an individual's cancer cells. The use of neoantigen-targeted therapies within precision oncology represents a strategy to tailor treatment to the specific genetic profile of each patient's tumor, providing a more personalized and effective treatment option. For instance, in March 2024, the Precision Oncology Clinical Trials & Statistics 2024 report published by Novotech, an Australia-based full-service clinical contract research organization focused on developing innovative therapeutics across all phases, noted that by November 2023, twelve treatments had received FDA approval for specific biomarker-selected indications, with six of these included in the NCCN guidelines. By the end of the year, 43% of the 217 FDA-approved oncology therapies were classified as precision oncology, with 78 of these therapies featuring DNA or NGS-detectable biomarkers, underscoring the growing importance of biomarker-driven treatments in cancer care. Thus, the rise in precision oncology is fueling the growth of the neoantigen-targeted therapies market.

Major companies in the neoantigen-targeted therapies market are pursuing a strategic partnership approach to personalize cancer therapies and address the challenges of existing immunotherapy in treating solid tumors. Strategic partnerships involve companies leveraging each other's strengths and resources to achieve mutual benefits and success. For example, in January 2023, BioNTech SE, a Germany-based biotechnology company, partnered with the Government of the United Kingdom to advance personalized mRNA cancer immunotherapies. This collaboration aims to deliver tailored treatments to as many as 10,000 patients by 2030, focusing on several critical areas, including the development of cancer immunotherapies, research on infectious disease vaccines, and the establishment of a research and development hub in Cambridge. The initiative will utilize the UK's clinical trial infrastructure and health data resources to enhance patient recruitment and select trial sites for BioNTech's mRNA treatments. The company plans to initiate its first clinical trials in the UK later this year, concentrating on cancer vaccines that could potentially be integrated into standard treatment protocols if proven effective.

Major companies in the neoantigen-targeted therapies market are adopting a strategic partnership approach to personalize neoantigen vaccines and monoclonal antibody drugs to tackle the challenges of existing immunotherapy in treating solid tumors. Strategic partnerships involve companies leveraging each other's strengths and resources for mutual benefit and success. For instance, in April 2023, Moderna, Inc., a US-based pharmaceutical and biotechnology company, collaborated with Merck & Co., Inc., a US-based pharmaceutical company, to launch mRNA-4157 (V940). This investigational individualized neoantigen therapy (INT) is designed to generate a tailored antitumor immune response based on the unique mutational signature of a patient's tumor. mRNA-4157 (V940) works by encoding up to 34 neoantigens to stimulate T cell responses, enhancing the body's ability to target and destroy tumor cells when combined with Merck's immunotherapy KEYTRUDA. This combination aims to improve recurrence-free survival in patients with high-risk resected melanoma.

In January 2023, AstraZeneca plc, a UK-based pharmaceutical company, acquired Neogene Therapeutics Inc. for $200 million. This acquisition is intended to enhance AstraZeneca's oncology portfolio, with a particular focus on developing transformative T-cell receptor (TCR) therapies that target neoantigens in solid tumors. Neogene's expertise in next-generation TCR-T therapies is expected to complement AstraZeneca's existing capabilities in the oncology field, allowing the company to advance its cancer treatment initiatives. Neogene Therapeutics Inc. is a US-based biotechnology company that specializes in neoantigen-targeted therapies.

Major companies operating in the neoantigen targeted therapies market include F. Hoffmann-La Roche AG, Merck and Co. Inc., Bristol Myers Squibb Company, Eli Lilly and Company, Kite Pharma Inc., Gilead Sciences Inc., Amgen Inc., Moderna Inc., BioNTech SE, Bavarian Nordic Inc., Advaxis Inc., Immatics NV, Precision Biologics Inc., Iovance Biotherapeutics Inc., Agenus Inc., Achilles Therapeutics Plc, Medigene AG, Gritstone Bio Inc., SQZ Biotechnologies Company, Aduro BioTech Inc., Inovio Pharmaceuticals Inc., Gradalis Inc., EpiVax Inc., ISA Pharmaceuticals BV, Vaxon Biotech SA, Ziopharm Oncology, Genocea Biosciences Inc., Cellular Biomedicine Group Inc., Immunovaccine Inc.

North America was the largest region in the neoantigen targeted therapies market in 2024. The regions covered in the neoantigen targeted therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the neoantigen targeted therapies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neoantigen targeted therapies market consists of revenues earned by entities by providing services such as the identification and characterization of neoantigens in individual patients, the selection and administration of the appropriate therapy, and the monitoring of patients' responses. The market value includes the value of related goods sold by the service provider or included within the service offering. Neoantigen targeted therapies also include the sale of neoantigen-based cancer vaccines and genetically modified T cells. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neoantigen Targeted Therapies Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neoantigen targeted therapies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neoantigen targeted therapies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neoantigen targeted therapies market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Monotherapy, Combination Therapy
2) By Immunotherapy Type: DNA Or RNA-Based Vaccines, Protein-Based Vaccines, Dendritic Cell Vaccines, TIL-Based Therapies
3) By Target Disease Indication: Colorectal Cancer, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Bone Cancer, Gynecological Cancer
4) By Route Of Administration: Intradermal, Intravenous, Subcutaneous
5) By Application: Medical Research Institution, Hospital, And Clinic, Other Applications
Subsegments:
1) By Monotherapy: Individual Neoantigen-Targeted Treatments
2) By Combination Therapy: Neoantigen-Targeted Therapies Combined With Other Immunotherapies; Neoantigen-Targeted Therapies Combined With Chemotherapy; Neoantigen-Targeted Therapies Combined With Targeted Therapies
Companies Mentioned: F. Hoffmann-La Roche AG; Merck and Co. Inc.; Bristol Myers Squibb Company; Eli Lilly and Company; Kite Pharma Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r25135

1. Executive Summary

2. Neoantigen Targeted Therapies Market Characteristics

3. Neoantigen Targeted Therapies Market Trends And Strategies

4. Neoantigen Targeted Therapies Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Neoantigen Targeted Therapies Growth Analysis And Strategic Analysis Framework

5.1. Global Neoantigen Targeted Therapies PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Neoantigen Targeted Therapies Market Growth Rate Analysis
5.4. Global Neoantigen Targeted Therapies Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Neoantigen Targeted Therapies Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Neoantigen Targeted Therapies Total Addressable Market (TAM)

6. Neoantigen Targeted Therapies Market Segmentation

6.1. Global Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monotherapy
Combination Therapy
6.2. Global Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
DNA Or RNA-Based Vaccines
Protein-Based Vaccines
Dendritic Cell Vaccines
TIL-Based Therapies
6.3. Global Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Colorectal Cancer
Renal Cell Carcinoma
Non-Small Cell Lung Cancer
Bone Cancer
Gynecological Cancer
6.4. Global Neoantigen Targeted Therapies Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Intradermal
Intravenous
Subcutaneous
6.5. Global Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Medical Research Institution
Hospital And Clinic
Other Applications
6.6. Global Neoantigen Targeted Therapies Market, Sub-Segmentation Of Monotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Individual Neoantigen-Targeted Treatments
6.7. Global Neoantigen Targeted Therapies Market, Sub-Segmentation Of Combination Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Neoantigen-Targeted Therapies Combined With Other Immunotherapies
Neoantigen-Targeted Therapies Combined With Chemotherapy
Neoantigen-Targeted Therapies Combined With Targeted Therapies

7. Neoantigen Targeted Therapies Market Regional And Country Analysis

7.1. Global Neoantigen Targeted Therapies Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Neoantigen Targeted Therapies Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Neoantigen Targeted Therapies Market

8.1. Asia-Pacific Neoantigen Targeted Therapies Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Neoantigen Targeted Therapies Market

9.1. China Neoantigen Targeted Therapies Market Overview
9.2. China Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Neoantigen Targeted Therapies Market

10.1. India Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Neoantigen Targeted Therapies Market

11.1. Japan Neoantigen Targeted Therapies Market Overview
11.2. Japan Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Neoantigen Targeted Therapies Market

12.1. Australia Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Neoantigen Targeted Therapies Market

13.1. Indonesia Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Neoantigen Targeted Therapies Market

14.1. South Korea Neoantigen Targeted Therapies Market Overview
14.2. South Korea Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Neoantigen Targeted Therapies Market

15.1. Western Europe Neoantigen Targeted Therapies Market Overview
15.2. Western Europe Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Neoantigen Targeted Therapies Market

16.1. UK Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Neoantigen Targeted Therapies Market

17.1. Germany Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Neoantigen Targeted Therapies Market

18.1. France Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Neoantigen Targeted Therapies Market

19.1. Italy Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Neoantigen Targeted Therapies Market

20.1. Spain Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Neoantigen Targeted Therapies Market

21.1. Eastern Europe Neoantigen Targeted Therapies Market Overview
21.2. Eastern Europe Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Neoantigen Targeted Therapies Market

22.1. Russia Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Neoantigen Targeted Therapies Market

23.1. North America Neoantigen Targeted Therapies Market Overview
23.2. North America Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Neoantigen Targeted Therapies Market

24.1. USA Neoantigen Targeted Therapies Market Overview
24.2. USA Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Neoantigen Targeted Therapies Market

25.1. Canada Neoantigen Targeted Therapies Market Overview
25.2. Canada Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Neoantigen Targeted Therapies Market

26.1. South America Neoantigen Targeted Therapies Market Overview
26.2. South America Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Neoantigen Targeted Therapies Market

27.1. Brazil Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Neoantigen Targeted Therapies Market

28.1. Middle East Neoantigen Targeted Therapies Market Overview
28.2. Middle East Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Neoantigen Targeted Therapies Market

29.1. Africa Neoantigen Targeted Therapies Market Overview
29.2. Africa Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Neoantigen Targeted Therapies Market Competitive Landscape And Company Profiles

30.1. Neoantigen Targeted Therapies Market Competitive Landscape
30.2. Neoantigen Targeted Therapies Market Company Profiles
- 30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Merck and Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Kite Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Neoantigen Targeted Therapies Market Other Major And Innovative Companies

31.1. Gilead Sciences Inc.
31.2. Amgen Inc.
31.3. Moderna Inc.
31.4. BioNTech SE
31.5. Bavarian Nordic Inc.
31.6. Advaxis Inc.
31.7. Immatics NV
31.8. Precision Biologics Inc.
31.9. Iovance Biotherapeutics Inc.
31.10. Agenus Inc.
31.11. Achilles Therapeutics Plc
31.12. Medigene AG
31.13. Gritstone Bio Inc.
31.14. SQZ Biotechnologies Company
31.15. Aduro BioTech Inc.

32. Global Neoantigen Targeted Therapies Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Neoantigen Targeted Therapies Market

34. Recent Developments In The Neoantigen Targeted Therapies Market

35. Neoantigen Targeted Therapies Market High Potential Countries, Segments and Strategies

35.1 Neoantigen Targeted Therapies Market In 2029 - Countries Offering Most New Opportunities
35.2 Neoantigen Targeted Therapies Market In 2029 - Segments Offering Most New Opportunities
35.3 Neoantigen Targeted Therapies Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer